KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Total Current Liabilities (2016 - 2025)

Novavax (NVAX) has 16 years of Total Current Liabilities data on record, last reported at $460.0 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 60.16% year-over-year to $460.0 million; the TTM value through Dec 2025 reached $460.0 million, down 60.16%, while the annual FY2025 figure was $460.0 million, 60.16% down from the prior year.
  • Total Current Liabilities reached $460.0 million in Q4 2025 per NVAX's latest filing, up from $389.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $2.5 billion in Q4 2022 and bottomed at $389.1 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 6266.85% in 2021, then plummeted 66.39% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $2.4 billion in 2021, then rose by 2.91% to $2.5 billion in 2022, then plummeted by 33.53% to $1.6 billion in 2023, then dropped by 29.4% to $1.2 billion in 2024, then crashed by 60.16% to $460.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $460.0 million in Q4 2025, $389.1 million in Q2 2025, and $422.2 million in Q1 2025.